Switching treatment for advanced kidney cancer in Chinese patients
Part of Cancer, Kidney & urinary clinical trials.
This study looks at switching to a different cancer drug (a TKI or a TKI plus immunotherapy) after your first treatment for advanced kidney cancer has stopped working or caused bad side effects. The goal is to see how well these second treatments work in Chinese patients, which could help choose a better option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced kidney cancer that has spread to other parts of the body.
- You must have already tried one first-line treatment: either a TKI (like sunitinib or pazopanib) or a TKI combined with an immunotherapy (like pembrolizumab or nivolumab), and it stopped working or caused bad side effects.
- You must be at least 18 years old and of Chinese descent (both parents and grandparents are Chinese).
- You should be in reasonably good health: able to care for yourself, with adequate blood counts and liver/kidney function.
- You cannot have serious heart problems, active infections, other cancers (in the last 3 years), or conditions that could affect your safety or the study results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial tests whether adding a cholesterol-lowering drug (atorvastatin) to the standard combination of two cancer drugs (axitinib and toripalimab) can improve outcomes for people with advanced clear cell kidney cancer that cannot be removed by surgery or has spread. The goal is to see if this three-drug approach is safe and effective.
This trial compares two new treatment options for advanced kidney cancer (clear cell type) that has worsened after immunotherapy. One group gets two oral drugs (vorolanib and everolimus) together; the other gets a standard targeted therapy (sunitinib).
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
Hear when a new RCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.